{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:41:21Z","timestamp":1791549681799,"version":"4.3.4"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02552-w","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:37:33Z","timestamp":1746765453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cathepsin B in urological tumors: unraveling its role and therapeutic potential"],"prefix":"10.1007","volume":"16","author":[{"given":"Zhaojie","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guansong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqiang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"3","key":"2552_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho AM, Laversanne M, Ferlay J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2025;156(7):1336\u201346.","journal-title":"Int J Cancer"},{"issue":"1","key":"2552_CR3","first-page":"64","volume":"11","author":"H Zi","year":"2024","unstructured":"Zi H, Liu M-Y, Luo L-S, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. 2024;11(1):64.","journal-title":"Mil Med Res"},{"issue":"12","key":"2552_CR4","doi-asserted-by":"publisher","first-page":"T297","DOI":"10.1530\/ERC-17-0145","volume":"24","author":"M Gamat","year":"2017","unstructured":"Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017;24(12):T297\u2013310.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2552_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","volume":"82","author":"S Gillessen","year":"2022","unstructured":"Gillessen S, Armstrong A, Attard G, et al. Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021. Eur Urol. 2022;82(1):115\u201341.","journal-title":"Eur Urol"},{"key":"2552_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"issue":"5","key":"2552_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","volume":"84","author":"ER Plimack","year":"2023","unstructured":"Plimack ER, Powles T, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 Study. Eur Urol. 2023;84(5):449\u201354.","journal-title":"Eur Urol"},{"issue":"6","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21147\/j.issn.1000-9604.2023.06.12","volume":"35","author":"Z Tuo","year":"2023","unstructured":"Tuo Z, Feng D, Jiang Z, et al. Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis. Chin J Cancer Res. 2023;35(6):686\u2013701.","journal-title":"Chin J Cancer Res"},{"key":"2552_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","volume":"76","author":"R Nadal","year":"2019","unstructured":"Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10\u201321.","journal-title":"Cancer Treat Rev"},{"key":"2552_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.semcancer.2018.07.010","volume":"53","author":"A Pi\u0161lar","year":"2018","unstructured":"Pi\u0161lar A, Jewett A, Kos J. Cysteine cathepsins: their biological and molecular significance in cancer stem cells. Semin Cancer Biol. 2018;53:168\u201377.","journal-title":"Semin Cancer Biol"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.canlet.2019.02.035","volume":"449","author":"O Mijanovi\u0107","year":"2019","unstructured":"Mijanovi\u0107 O, Brankovi\u0107 A, Panin AN, et al. Cathepsin B: a sellsword of cancer progression. Cancer Lett. 2019;449:207\u201314.","journal-title":"Cancer Lett"},{"issue":"12","key":"2552_CR12","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1080\/15548627.2016.1239679","volume":"12","author":"SM Man","year":"2016","unstructured":"Man SM, Kanneganti T-D. Regulation of lysosomal dynamics and autophagy by CTSB\/cathepsin B. Autophagy. 2016;12(12):2504\u20135.","journal-title":"Autophagy"},{"issue":"16","key":"2552_CR13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300099120","volume":"120","author":"MY Chou","year":"2023","unstructured":"Chou MY, Liu D, An J, et al. B cell peripheral tolerance is promoted by cathepsin B protease. Proc Natl Acad Sci U S A. 2023;120(16): e2300099120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2552_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/path.1711450404","volume":"145","author":"AJ Howie","year":"1985","unstructured":"Howie AJ, Burnett D, Crocker J. The distribution of cathepsin B in human tissues. J Pathol. 1985;145(4):307\u201314.","journal-title":"J Pathol"},{"issue":"1","key":"2552_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4049\/jimmunol.181.1.690","volume":"181","author":"S-D Ha","year":"2008","unstructured":"Ha S-D, Martins A, Khazaie K, et al. Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages. J Immunol. 2008;181(1):690\u20137.","journal-title":"J Immunol"},{"issue":"20","key":"2552_CR16","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1073\/pnas.83.20.7721","volume":"83","author":"SJ Chan","year":"1986","unstructured":"Chan SJ, San Segundo B, McCormick MB, et al. Nucleotide and predicted amino acid sequences of cloned human and mouse preprocathepsin B cDNAs. Proc Natl Acad Sci U S A. 1986;83(20):7721\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2552_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2990.1993.tb00420.x","volume":"19","author":"D McCormick","year":"1993","unstructured":"McCormick D. Secretion of cathepsin B by human gliomas in vitro. Neuropathol Appl Neurobiol. 1993;19(2):146\u201351.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2552_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116329","volume":"269","author":"F Liu","year":"2024","unstructured":"Liu F, Zhou T, Zhang S, et al. Cathepsin B: the dawn of tumor therapy. Eur J Med Chem. 2024;269: 116329.","journal-title":"Eur J Med Chem"},{"issue":"24","key":"2552_CR19","first-page":"6517","volume":"54","author":"J Rozhin","year":"1994","unstructured":"Rozhin J, Sameni M, Ziegler G, et al. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994;54(24):6517\u201325.","journal-title":"Cancer Res"},{"issue":"1","key":"2552_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0014-5793(90)81151-D","volume":"269","author":"RA Maciewicz","year":"1990","unstructured":"Maciewicz RA, Wotton SF, Etherington DJ, et al. Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L. FEBS Lett. 1990;269(1):189\u201393.","journal-title":"FEBS Lett"},{"issue":"17","key":"2552_CR21","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1093\/emboj\/20.17.4629","volume":"20","author":"V Turk","year":"2001","unstructured":"Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001;20(17):4629\u201333.","journal-title":"EMBO J"},{"issue":"17","key":"2552_CR22","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1021\/acs.biochem.2c00358","volume":"61","author":"MC Yoon","year":"2022","unstructured":"Yoon MC, Hook V, O\u2019Donoghue AJ. Cathepsin B dipeptidyl carboxypeptidase and endopeptidase activities demonstrated across a broad pH range. Biochemistry. 2022;61(17):1904\u201314.","journal-title":"Biochemistry"},{"issue":"8","key":"2552_CR23","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/j.bbagen.2014.03.017","volume":"1840","author":"M Fonovi\u0107","year":"2014","unstructured":"Fonovi\u0107 M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta. 2014;1840(8):2560\u201370.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2552_CR24","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1016\/S0021-9258(19)67767-7","volume":"266","author":"H Kobayashi","year":"1991","unstructured":"Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991;266(8):5147\u201352.","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11010-018-3460-3","volume":"454","author":"S Kumari","year":"2019","unstructured":"Kumari S, Mukherjee A, Mukhopadhyay CK. Dopamine promotes cathepsin B-mediated amyloid precursor protein degradation by reactive oxygen species-sensitive mechanism in neuronal cell. Mol Cell Biochem. 2019;454(1\u20132):153\u201363.","journal-title":"Mol Cell Biochem"},{"issue":"23","key":"2552_CR26","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1523\/JNEUROSCI.3214-17.2018","volume":"38","author":"AP Tran","year":"2018","unstructured":"Tran AP, Sundar S, Yu M, et al. Modulation of receptor protein tyrosine phosphatase sigma increases chondroitin sulfate proteoglycan degradation through Cathepsin B secretion to enhance axon outgrowth. J Neurosci. 2018;38(23):5399\u2013414.","journal-title":"J Neurosci"},{"issue":"1","key":"2552_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12660","volume":"28","author":"C Mazzotta","year":"2021","unstructured":"Mazzotta C, Marden G, Farina A, et al. FLI1 and ERG protein degradation is regulated via Cathepsin B lysosomal pathway in human dermal microvascular endothelial cells. Microcirculation. 2021;28(1): e12660.","journal-title":"Microcirculation"},{"issue":"1","key":"2552_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4143\/crt.2019.145","volume":"52","author":"G-P Zhang","year":"2020","unstructured":"Zhang G-P, Yue X, Li S-Q. Cathepsin C interacts with TNF-\u03b1\/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma. Cancer Res Treat. 2020;52(1):10\u201323.","journal-title":"Cancer Res Treat"},{"key":"2552_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fcell.2020.00167","volume":"8","author":"A Chevriaux","year":"2020","unstructured":"Chevriaux A, Pilot T, Derang\u00e8re V, et al. Cathepsin B is required for NLRP3 inflammasome activation in macrophages, through NLRP3 interaction. Front Cell Dev Biol. 2020;8:167.","journal-title":"Front Cell Dev Biol"},{"key":"2552_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172795","volume":"865","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen Y, Zhang Y, et al. Contribution of cathepsin B-dependent Nlrp3 inflammasome activation to nicotine-induced endothelial barrier dysfunction. Eur J Pharmacol. 2019;865: 172795.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2552_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","volume":"1824","author":"V Turk","year":"2012","unstructured":"Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta. 2012;1824(1):68\u201388.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2552_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/138161207780162962","volume":"13","author":"O Vasiljeva","year":"2007","unstructured":"Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007;13(4):387\u2013403.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"2552_CR33","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1038\/s41598-022-08346-2","volume":"12","author":"K Ma","year":"2022","unstructured":"Ma K, Chen X, Liu W, et al. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Sci Rep. 2022;12(1):4295.","journal-title":"Sci Rep"},{"key":"2552_CR34","doi-asserted-by":"crossref","unstructured":"Yadati T, Houben T, Bitorina A, et al. The ins and outs of cathepsins: physiological function and role in disease management. Cells, 2020, 9(7).","DOI":"10.3390\/cells9071679"},{"issue":"1","key":"2552_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"Z-D Shi","year":"2023","unstructured":"Shi Z-D, Pang K, Wu Z-X, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8(1):113.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2552_CR36","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.yexcr.2012.03.005","volume":"318","author":"MH \u010cesen","year":"2012","unstructured":"\u010cesen MH, Pegan K, Spes A, et al. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res. 2012;318(11):1245\u201351.","journal-title":"Exp Cell Res"},{"issue":"1\u20132","key":"2552_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbi.2006.04.013","volume":"163","author":"A Terman","year":"2006","unstructured":"Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chem Biol Interact. 2006;163(1\u20132):29\u201337.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"2552_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1053\/j.gastro.2005.05.022","volume":"129","author":"ME Guicciardi","year":"2005","unstructured":"Guicciardi ME, Bronk SF, Werneburg NW, et al. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. Gastroenterology. 2005;129(1):269\u201384.","journal-title":"Gastroenterology"},{"issue":"9","key":"2552_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1172\/JCI9914","volume":"106","author":"ME Guicciardi","year":"2000","unstructured":"Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Investig. 2000;106(9):1127\u201337.","journal-title":"J Clin Investig"},{"key":"2552_CR40","doi-asserted-by":"crossref","unstructured":"Chen C, Ahmad M J, Ye T, et al. Cathepsin B regulates mice granulosa cells' apoptosis and proliferation in vitro. Int J Mol Sci, 2021, 22(21).","DOI":"10.3390\/ijms222111827"},{"issue":"6","key":"2552_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12487","volume":"51","author":"N Chen","year":"2018","unstructured":"Chen N, Ou Z, Zhang W, et al. Cathepsin B regulates non-canonical NLRP3 inflammasome pathway by modulating activation of caspase-11 in Kupffer cells. Cell Prolif. 2018;51(6): e12487.","journal-title":"Cell Prolif"},{"issue":"5","key":"2552_CR42","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"4","key":"2552_CR43","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.bbrc.2020.10.035","volume":"533","author":"F Kuang","year":"2020","unstructured":"Kuang F, Liu J, Li C, et al. Cathepsin B is a mediator of organelle-specific initiation of ferroptosis. Biochem Biophys Res Commun. 2020;533(4):1464\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2552_CR44","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.bbrc.2018.07.078","volume":"503","author":"H Gao","year":"2018","unstructured":"Gao H, Bai Y, Jia Y, et al. Ferroptosis is a lysosomal cell death process. Biochem Biophys Res Commun. 2018;503(3):1550\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2552_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118928","volume":"1868","author":"P Nagakannan","year":"2021","unstructured":"Nagakannan P, Islam MI, Conrad M, et al. Cathepsin B is an executioner of ferroptosis. Biochim Biophys Acta Mol Cell Res. 2021;1868(3): 118928.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"42","key":"2552_CR46","doi-asserted-by":"publisher","first-page":"30094","DOI":"10.1074\/jbc.M113.494286","volume":"288","author":"S Li","year":"2013","unstructured":"Li S, Du L, Zhang L, et al. Cathepsin B contributes to autophagy-related 7 (Atg7)-induced nod-like receptor 3 (NLRP3)-dependent proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line. J Biol Chem. 2013;288(42):30094\u2013104.","journal-title":"J Biol Chem"},{"issue":"9","key":"2552_CR47","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1080\/15548627.2020.1827779","volume":"17","author":"D-H Lee","year":"2021","unstructured":"Lee D-H, Park S-H, Ahn J, et al. Mir214-3p and Hnf4a\/Hnf4\u03b1 reciprocally regulate Ulk1 expression and autophagy in nonalcoholic hepatic steatosis. Autophagy. 2021;17(9):2415\u201331.","journal-title":"Autophagy"},{"issue":"4","key":"2552_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbalip.2016.01.006","volume":"1861","author":"C Ward","year":"2016","unstructured":"Ward C, Martinez-Lopez N, Otten EG, et al. Autophagy, lipophagy and lysosomal lipid storage disorders. Biochim Biophys Acta. 2016;1861(4):269\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"2552_CR49","doi-asserted-by":"crossref","unstructured":"Zaj\u0105c A, Maciejczyk A, Sumorek-Wiadro J, et al. The Role of Bcl-2 and Beclin-1 Complex in \"Switching\" between apoptosis and autophagy in human glioma cells upon LY294002 and sorafenib treatment. Cells, 2023, 12(23).","DOI":"10.3390\/cells12232670"},{"issue":"2","key":"2552_CR50","first-page":"214","volume":"2","author":"RT Marquez","year":"2012","unstructured":"Marquez RT, Xu L. Bcl-2: Beclin 1 complex: multiple, mechanisms regulating autophagy\/apoptosis toggle switch. Am J Cancer Res. 2012;2(2):214\u201321.","journal-title":"Am J Cancer Res"},{"issue":"7723","key":"2552_CR51","doi-asserted-by":"publisher","first-page":"E30","DOI":"10.1038\/s41586-018-0270-4","volume":"561","author":"\u00c1F Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez \u00c1F, Sebti S, Wei Y, et al. Author Correction: Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;561(7723):E30.","journal-title":"Nature"},{"issue":"12","key":"2552_CR52","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/CIRCULATIONAHA.111.066712","volume":"125","author":"XW Cheng","year":"2012","unstructured":"Cheng XW, Shi G-P, Kuzuya M, et al. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation. 2012;125(12):1551\u201362.","journal-title":"Circulation"},{"issue":"6","key":"2552_CR53","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/pmic.200401030","volume":"5","author":"MPA Ebert","year":"2005","unstructured":"Ebert MPA, Kr\u00fcger S, Fogeron M-L, et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005;5(6):1693\u2013704.","journal-title":"Proteomics"},{"issue":"5","key":"2552_CR54","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/BF03401787","volume":"6","author":"JH McKerrow","year":"2000","unstructured":"McKerrow JH, Bhargava V, Hansell E, et al. A functional proteomics screen of proteases in colorectal carcinoma. Mol Med. 2000;6(5):450\u201360.","journal-title":"Mol Med"},{"issue":"6","key":"2552_CR55","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/1615-9861(200206)2:6<706::AID-PROT706>3.0.CO;2-E","volume":"2","author":"C Srisomsap","year":"2002","unstructured":"Srisomsap C, Subhasitanont P, Otto A, et al. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics. 2002;2(6):706\u201312.","journal-title":"Proteomics"},{"issue":"22","key":"2552_CR56","first-page":"6740","volume":"62","author":"JD Wulfkuhle","year":"2002","unstructured":"Wulfkuhle JD, Sgroi DC, Krutzsch H, et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 2002;62(22):6740\u20139.","journal-title":"Cancer Res"},{"issue":"10","key":"2552_CR57","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrc1949","volume":"6","author":"MM Mohamed","year":"2006","unstructured":"Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer. 2006;6(10):764\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2552_CR58","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.ejca.2004.03.011","volume":"40","author":"AM Troy","year":"2004","unstructured":"Troy AM, Sheahan K, Mulcahy HE, et al. Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer. 2004;40(10):1610\u20136.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2552_CR59","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0046-8177(99)90094-1","volume":"30","author":"K Hirai","year":"1999","unstructured":"Hirai K, Yokoyama M, Asano G, et al. Expression of cathepsin B and cystatin C in human colorectal cancer. Hum Pathol. 1999;30(6):680\u20136.","journal-title":"Hum Pathol"},{"issue":"2","key":"2552_CR60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3892\/or.2013.2496","volume":"30","author":"W Bao","year":"2013","unstructured":"Bao W, Fan Q, Luo X, et al. Silencing of Cathepsin B suppresses the proliferation and invasion of endometrial cancer. Oncol Rep. 2013;30(2):723\u201330.","journal-title":"Oncol Rep"},{"issue":"12","key":"2552_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.170","volume":"3","author":"VR Gogineni","year":"2012","unstructured":"Gogineni VR, Gupta R, Nalla AK, et al. uPAR and cathepsin B shRNA impedes TGF-\u03b21-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway. Cell Death Dis. 2012;3(12): e439.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2552_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123711","volume":"10","author":"T Rajah","year":"2015","unstructured":"Rajah T, Chow SC. Suppression of human T cell proliferation mediated by the cathepsin B Inhibitor, z-FA-FMK is due to oxidative stress. PLoS ONE. 2015;10(4): e0123711.","journal-title":"PLoS ONE"},{"issue":"6","key":"2552_CR63","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.7150\/ijms.54206","volume":"18","author":"S Peng","year":"2021","unstructured":"Peng S, Yang Q, Li H, et al. CTSB knockdown inhibits proliferation and tumorigenesis in HL-60 cells. Int J Med Sci. 2021;18(6):1484\u201391.","journal-title":"Int J Med Sci"},{"issue":"35","key":"2552_CR64","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.3748\/wjg.v21.i35.10137","volume":"21","author":"T Lei","year":"2015","unstructured":"Lei T, Ling X. IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J Gastroenterol. 2015;21(35):10137\u201349.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2552_CR65","first-page":"1265","volume":"22","author":"JX Li","year":"2018","unstructured":"Li JX, Ding XM, Han S, et al. mir-637 inhibits the proliferation of cholangiocarcinoma cell QBC939 through interfering CTSB expression. Eur Rev Med Pharmacol Sci. 2018;22(5):1265\u201376.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"30","key":"2552_CR66","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.1038\/onc.2008.59","volume":"27","author":"O Vasiljeva","year":"2008","unstructured":"Vasiljeva O, Korovin M, Gajda M, et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene. 2008;27(30):4191\u20139.","journal-title":"Oncogene"},{"issue":"20","key":"2552_CR67","doi-asserted-by":"publisher","first-page":"9821","DOI":"10.7150\/thno.62187","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Liang Y, Lian C, et al. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis. Theranostics. 2021;11(20):9821\u201332.","journal-title":"Theranostics"},{"issue":"12","key":"2552_CR68","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1158\/1535-7163.MCT-05-0531","volume":"5","author":"CS Gondi","year":"2006","unstructured":"Gondi CS, Kandhukuri N, Kondraganti S, et al. RNA interference-mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8-mediated apoptosis in SNB19 human glioma cells. Mol Cancer Ther. 2006;5(12):3197\u2013208.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"2552_CR69","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/bcr3058","volume":"13","author":"BC Victor","year":"2011","unstructured":"Victor BC, Anbalagan A, Mohamed MM, et al. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res. 2011;13(6):R115.","journal-title":"Breast Cancer Res"},{"issue":"24","key":"2552_CR70","doi-asserted-by":"publisher","first-page":"13533","DOI":"10.1128\/JVI.02095-12","volume":"86","author":"W-N Chen","year":"2012","unstructured":"Chen W-N, Chen J-Y, Jiao B-Y, et al. Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion. J Virol. 2012;86(24):13533\u201341.","journal-title":"J Virol"},{"issue":"4","key":"2552_CR71","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1074\/jbc.M112.397398","volume":"288","author":"A Shimizu","year":"2013","unstructured":"Shimizu A, Nakayama H, Wang P, et al. Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein. J Biol Chem. 2013;288(4):2210\u201322.","journal-title":"J Biol Chem"},{"issue":"5","key":"2552_CR72","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1535-6108(04)00111-4","volume":"5","author":"JA Joyce","year":"2004","unstructured":"Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5(5):443\u201353.","journal-title":"Cancer Cell"},{"key":"2552_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2021.09.036","volume":"523","author":"X Li","year":"2021","unstructured":"Li X, Wei Z, Yu H, et al. Secretory autophagy-induced bladder tumour-derived extracellular vesicle secretion promotes angiogenesis by activating the TPX2-mediated phosphorylation of the AURKA-PI3K-AKT axis. Cancer Lett. 2021;523:10\u201328.","journal-title":"Cancer Lett"},{"issue":"9","key":"2552_CR74","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/cgt.2010.16","volume":"17","author":"AK Nalla","year":"2010","unstructured":"Nalla AK, Gorantla B, Gondi CS, et al. Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther. 2010;17(9):599\u2013613.","journal-title":"Cancer Gene Ther"},{"key":"2552_CR75","doi-asserted-by":"crossref","unstructured":"Retraction: uPAR\/Cathepsin B Overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR\/Cathepsin B down regulated meningioma. PLoS One, 2020, 15(1): e0228681.","DOI":"10.1371\/journal.pone.0228681"},{"issue":"12","key":"2552_CR76","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/sj.onc.1207338","volume":"23","author":"N Yanamandra","year":"2004","unstructured":"Yanamandra N, Gumidyala KV, Waldron KG, et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene. 2004;23(12):2224\u201330.","journal-title":"Oncogene"},{"key":"2552_CR77","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.freeradbiomed.2013.09.028","volume":"65","author":"LL Camargo","year":"2013","unstructured":"Camargo LL, Babelova A, Mieth A, et al. Endo-PDI is required for TNF\u03b1-induced angiogenesis. Free Radic Biol Med. 2013;65:1398\u2013407.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"2552_CR78","first-page":"973","volume":"5","author":"R Weiss","year":"1994","unstructured":"Weiss R, Fair W, Cordoncardo C. Characterization of protease expression in human prostate-cancer cell-lines. Int J Oncol. 1994;5(4):973\u20138.","journal-title":"Int J Oncol"},{"issue":"3","key":"2552_CR79","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1593\/neo.04349","volume":"7","author":"I Podgorski","year":"2005","unstructured":"Podgorski I, Linebaugh BE, Sameni M, et al. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia. 2005;7(3):207\u201323.","journal-title":"Neoplasia"},{"issue":"5A","key":"2552_CR80","first-page":"3135","volume":"27","author":"AA Sinha","year":"2007","unstructured":"Sinha AA, Morgan JL, Buus RJ, et al. Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients. Anticancer Res. 2007;27(5A):3135\u201341.","journal-title":"Anticancer Res"},{"issue":"2","key":"2552_CR81","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ar.1092350207","volume":"235","author":"AA Sinha","year":"1993","unstructured":"Sinha AA, Gleason DF, Deleon OF, et al. Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec. 1993;235(2):233\u201340.","journal-title":"Anat Rec"},{"issue":"3","key":"2552_CR82","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ar.1092410309","volume":"241","author":"AA Sinha","year":"1995","unstructured":"Sinha AA, Gleason DF, Staley NA, et al. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis. Anat Rec. 1995;241(3):353\u201362.","journal-title":"Anat Rec"},{"issue":"9","key":"2552_CR83","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1359\/jbmr.1998.13.9.1420","volume":"13","author":"V Everts","year":"1998","unstructured":"Everts V, Delaiss\u00e9 JM, Korper W, et al. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res. 1998;13(9):1420\u201330.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2552_CR84","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jcb.240580106","volume":"58","author":"N Sch\u00fctze","year":"1995","unstructured":"Sch\u00fctze N, Oursler MJ, Nolan J, et al. Zeolite A inhibits osteoclast-mediated bone resorption in vitro. J Cell Biochem. 1995;58(1):39\u201346.","journal-title":"J Cell Biochem"},{"issue":"10","key":"2552_CR85","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1096\/fasebj.13.10.1219","volume":"13","author":"V Everts","year":"1999","unstructured":"Everts V, Korper W, Jansen DC, et al. Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J. 1999;13(10):1219\u201330.","journal-title":"FASEB J"},{"issue":"9","key":"2552_CR86","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/1878-0261.12360","volume":"12","author":"A Kumar","year":"2018","unstructured":"Kumar A, Dhar S, Campanelli G, et al. MTA1 drives malignant progression and bone metastasis in prostate cancer. Mol Oncol. 2018;12(9):1596\u2013607.","journal-title":"Mol Oncol"},{"issue":"9","key":"2552_CR87","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ijc.27480","volume":"131","author":"TH Beckham","year":"2012","unstructured":"Beckham TH, Lu P, Cheng JC, et al. Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B. Int J Cancer. 2012;131(9):2034\u201343.","journal-title":"Int J Cancer"},{"issue":"3","key":"2552_CR88","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/jcmm.14077","volume":"23","author":"Y Wang","year":"2019","unstructured":"Wang Y, Niu H, Hu Z, et al. Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1. J Cell Mol Med. 2019;23(3):1798\u2013812.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2552_CR89","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0022-5347(17)39595-2","volume":"144","author":"RE Weiss","year":"1990","unstructured":"Weiss RE, Liu BC, Ahlering T, et al. Mechanisms of human bladder tumor invasion: role of protease cathepsin B. J Urol. 1990;144(3):798\u2013804.","journal-title":"J Urol"},{"issue":"2","key":"2552_CR90","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/cncr.11493","volume":"98","author":"AM Eij\u00e1n","year":"2003","unstructured":"Eij\u00e1n AM, Sandes EO, Riveros MD, et al. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion. Cancer. 2003;98(2):262\u20138.","journal-title":"Cancer"},{"key":"2552_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.110869","volume":"389","author":"C-C Kao","year":"2024","unstructured":"Kao C-C, Lai C-R, Lin Y-H, et al. GW4064 inhibits migration and invasion through cathepsin B and MMP2 downregulation in human bladder cancer. Chem Biol Interact. 2024;389: 110869.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"2552_CR92","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/jcla.21483","volume":"26","author":"K Kotaska","year":"2012","unstructured":"Kotaska K, Dusek P, Prusa R, et al. Urine and serum cathepsin B concentrations in the transitional cell carcinoma of the bladder. J Clin Lab Anal. 2012;26(2):61\u20135.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"2552_CR93","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41389-019-0121-7","volume":"8","author":"C-H Chen","year":"2019","unstructured":"Chen C-H, Bhasin S, Khanna P, et al. Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. Oncogenesis. 2019;8(3):15.","journal-title":"Oncogenesis"},{"key":"2552_CR94","doi-asserted-by":"crossref","unstructured":"Rudzinska-Radecka M, Frolova AS, Balakireva AV, et al. In silico, in vitro, and clinical investigations of Cathepsin B and Stefin A mRNA expression and a correlation analysis in kidney cancer. Cells, 2022, 11(9).","DOI":"10.3390\/cells11091455"},{"issue":"2","key":"2552_CR95","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41419-021-03511-3","volume":"12","author":"L Li","year":"2021","unstructured":"Li L, Zhao S, Liu Z, et al. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway. Cell Death Dis. 2021;12(2):220.","journal-title":"Cell Death Dis"},{"key":"2552_CR96","doi-asserted-by":"crossref","unstructured":"Davalieva K, Kiprijanovska S, Maleva Kostovska I, et al. Comparative proteomics analysis of urine reveals down-regulation of acute phase response signaling and LXR\/RXR activation pathways in prostate cancer. Proteomes, 2017, 6(1).","DOI":"10.3390\/proteomes6010001"},{"issue":"3","key":"2552_CR97","first-page":"719","volume":"30","author":"J Qian","year":"2010","unstructured":"Qian J, Bostwick DG, Iczkowski KA, et al. Characterization of prostate cancer in needle biopsy by cathepsin B, cell proliferation and DNA ploidy. Anticancer Res. 2010;30(3):719\u201325.","journal-title":"Anticancer Res"},{"issue":"27","key":"2552_CR98","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1021\/acs.analchem.1c02145","volume":"93","author":"X Chen","year":"2021","unstructured":"Chen X, Ren X, Zhu Y, et al. Cathepsin B-activated fluorescent and photoacoustic imaging of tumor. Anal Chem. 2021;93(27):9304\u20138.","journal-title":"Anal Chem"},{"key":"2552_CR99","doi-asserted-by":"crossref","unstructured":"Liu Y, Liang J, Zhang Y, et al. Drug resistance and tumor immune microenvironment: an overview of current understandings (Review). Int J Oncol, 2024, 65(4).","DOI":"10.3892\/ijo.2024.5684"},{"issue":"1","key":"2552_CR100","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng F, Liao M, Qin R, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7(1):286.","journal-title":"Signal Transduct Target Ther"},{"key":"2552_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104390","volume":"147","author":"K-H Ho","year":"2019","unstructured":"Ho K-H, Cheng C-H, Chou C-M, et al. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Pharmacol Res. 2019;147: 104390.","journal-title":"Pharmacol Res"},{"key":"2552_CR102","doi-asserted-by":"crossref","unstructured":"Shi Q, Shen Q, Liu Y, et al. Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell, 2022, 40(10).","DOI":"10.1016\/j.ccell.2022.08.012"},{"key":"2552_CR103","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejmech.2014.03.073","volume":"79","author":"A Bechara","year":"2014","unstructured":"Bechara A, Barbosa CMV, Paredes-Gamero EJ, et al. Palladacycle (BPC) antitumour activity against resistant and metastatic cell lines: the relationship with cytosolic calcium mobilisation and cathepsin B activity. Eur J Med Chem. 2014;79:24\u201333.","journal-title":"Eur J Med Chem"},{"key":"2552_CR104","doi-asserted-by":"crossref","unstructured":"Cho H, Shim M K, Yang S, et al. Cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy. Pharmaceutics, 2021, 14(1).","DOI":"10.3390\/pharmaceutics14010083"},{"key":"2552_CR105","doi-asserted-by":"crossref","unstructured":"Herceg V, Bouilloux J, Janikowska K, et al. Cathepsin B-cleavable cyclopeptidic chemotherapeutic prodrugs. Molecules, 2020, 25(18).","DOI":"10.3390\/molecules25184285"},{"key":"2552_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121189","volume":"279","author":"J Kim","year":"2021","unstructured":"Kim J, Shim MK, Cho Y-J, et al. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279: 121189.","journal-title":"Biomaterials"},{"issue":"8","key":"2552_CR107","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1021\/acsnano.3c11958","volume":"18","author":"S Jiang","year":"2024","unstructured":"Jiang S, Li W, Yang J, et al. Cathepsin B-responsive programmed brain targeted delivery system for chemo-immunotherapy combination therapy of glioblastoma. ACS Nano. 2024;18(8):6445\u201362.","journal-title":"ACS Nano"},{"issue":"32","key":"2552_CR108","doi-asserted-by":"publisher","first-page":"53352","DOI":"10.18632\/oncotarget.18410","volume":"8","author":"H Han","year":"2017","unstructured":"Han H, Li J, Feng X, et al. Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells. Oncotarget. 2017;8(32):53352\u201365.","journal-title":"Oncotarget"},{"key":"2552_CR109","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jconrel.2020.12.042","volume":"330","author":"S Zeng","year":"2021","unstructured":"Zeng S, Ou H, Gao Z, et al. HCPT-peptide prodrug with tumor microenvironment -responsive morphology transformable characteristic for boosted bladder tumor chemotherapy. J Control Release. 2021;330:715\u201325.","journal-title":"J Control Release"},{"key":"2552_CR110","doi-asserted-by":"crossref","unstructured":"Lee S, Song S J, Lee J, et al. Cathepsin B-responsive liposomes for controlled anticancer drug delivery in Hep G2 Cells. Pharmaceutics, 2020, 12(9).","DOI":"10.3390\/pharmaceutics12090876"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02552-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:03:54Z","timestamp":1746770634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02552-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02552-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"707"}}